Form 4: Quest Diagnostics Director Sells Shares

Quest Diagnostics Director Gary M. Pfeiffer sold 1,482 shares of common stock and transferred phantom stock units.

Summary

• Gary M. Pfeiffer, a Director of Quest Diagnostics Inc. (DGX), reported transactions involving company securities.
• On October 22, 2025, Pfeiffer disposed of 1,482 shares of common stock at a price of $182.4 per share.
• Following this transaction, Pfeiffer directly beneficially owns 29,431 shares of common stock.
• On October 23, 2025, Pfeiffer transferred 4,413.284 phantom stock units from the company stock fund to another investment option within the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors.
• These phantom stock units were payable in cash and represented a like number of common stock shares, with an implied value of $190.58 per unit.
• The amount of phantom stock units transferred includes shares acquired via dividend reinvestment since the date of Pfeiffer's last Form 4 filing.
• The common stock transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (a sale under a 10b5-1 plan and an intra-plan transfer of deferred compensation units) by a director. These types of transactions are generally not indicative of significant positive or negative company-specific news.

Positives

• The common stock sale was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary transaction for personal financial planning.
• Director Gary M. Pfeiffer retains a significant direct beneficial ownership of 29,431 common shares after the reported transactions, demonstrating continued alignment with shareholder interests.

Negatives

• A director selling common stock, even under a pre-arranged plan, could be perceived by some investors as a slight negative signal, though often it is for personal financial management.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report reflects an individual director's personal financial management and does not provide broader insights into industry trends or competitive positioning for Quest Diagnostics.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by a director, particularly under a 10b5-1 plan, is unlikely to have a material impact on the company's stock price or long-term shareholder value. The director still holds a substantial number of shares.

Key Dates

Keywords

Quest Diagnostics, DGX, Gary M. Pfeiffer, Director, Insider Sale, Form 4, Common Stock, Phantom Stock, 10b5-1 Plan, Deferred Compensation